Results 11 to 20 of about 8,893 (235)

Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety [PDF]

Cardiovascular Diabetology
Background Glucagon like peptide-1 receptor agonist (GLP-1RA) use in individuals with high atherosclerotic cardiovascular disease (ASCVD) risk reduces major adverse cardiovascular events (MACE). However, its clinical impact, in terms of numbers needed to
Ansel Shao Pin Tang, Jovan Teng Yuan Hsu, Sheena Kar Shuan Chong, Jingxuan Quek, Genevieve Shek, Farisah Sulaimi, Kai En Chan, Vickram Vijay Anand, Bryan Chong, Anurag Mehta, Sue-Anne Toh, Mark Muthiah, Georgios K. Dimitriadis, Carel W. le Roux, Mark Yan-Yee Chan, Mamas Andreas Mamas, Yip Han Chin, Nicholas W. S. Chew   +17 more
doaj   +6 more sources

Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment

Therapeutic Advances in Endocrinology and Metabolism, 2023
Background: Patients with type 1 diabetes mellitus (T1DM) may have suboptimal glucose control and are interested in the use of adjuvant therapies. Objectives: To determine, from the patients’ perspective, the reasons for initiation of glucagon-like ...
Khary Edwards, Aleksandra Uruska, Anna Duda-Sobczak, Dorota Zozulinska-Ziolkiewicz, Ildiko Lingvay   +4 more
doaj   +1 more source

Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data

Frontiers in Endocrinology, 2022
Clinical studies after marketing have shown that the use of glucagon-like peptide-1 receptor agonist(GLP-1RA) may lead to acute kidney injury(AKI). However, few epidemiological studies have investigated the risk, clinical features, and outcomes of AKI ...
Shichao Dong, Chuan Sun
doaj   +1 more source

Real-World Utilization and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists Dosed Weekly and Daily in Patients with Type 2 Diabetes Mellitus: Results from Retrospective Electronic Medical Records in China [PDF]

Diabetes, Metabolic Syndrome and Obesity
Zhen Ruan,1,* Xianwen Chen,1,* Menghuan Song,1 Ruxu Jia,2 Hang Luo,3 Carolina Oi Lam Ung,1,4,5 Hao Hu1,4,5 1State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, Macau SAR,
Ruan Z, Chen X, Song M, Jia R, Luo H, Ung COL, Hu H   +6 more
doaj   +2 more sources

GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice [PDF]

, 2022
Dual agonists activating the peroxisome proliferator-activated receptors alpha and gamma (PPARɑ/ɣ) have beneficial effects on glucose and lipid metabolism in patients with type 2 diabetes, but their development was discontinued due to potential adverse ...
Bakhti, Mostafa, Bastidas-Ponce, Aimee, Baugé, Eric, Campbell, Jonathan E., Capozzi, Megan, Clemmensen, Christoffer, Collden, Gustav, Cota, Perla, DiMarchi, Richard D., Douros, Jon, Drucker, Daniel J., DuBois, Barent, Feuchtinger, Annette, Finan, Brian, Garcia-Caceres, Cristina, Grandl, Gerald, Harger, Alex, Hennuyer, Nathalie, Herzig, Stephan, Hofmann, Susanna M., Klingelhuber, Felix, Knerr, Patrick J., Krahmer, Natalie, Kulaj, Konxhe, Lalloyer, Fanny, Lickert, Heiko, Liskiewicz, Arek, Liskiewicz, Daniela, Maity, Gandhari, Müller, Timo D., Novikoff, Aaron, Perez-Tilve, Diego, Prakash, Sneha, Quarta, Carmelo, Sanchez-Garrido, Miguel A., Staels, Bart, Stemmer, Kerstin, Tschöp, Matthias H., Yang, Bin, Zhang, Qian   +39 more
core   +4 more sources

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes:a substudy of the SUSTAIN 8 randomised, controlled clinical trial [PDF]

, 2020
Aims/hypothesis: Intra-abdominal or visceral obesity is associated with insulin resistance and an increased risk for cardiovascular disease. This study aimed to compare the effects of semaglutide 1.0 mg and canagliflozin 300 mg on body composition in a ...
Catarig, Andrei-Mircea, Frias, Juan P., Lausvig, Nanna L., le Roux, Carel W., Lingvay, Ildiko, McCrimmon, Rory, Thielke, Desirée   +6 more
core   +2 more sources

Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis

European Psychiatry, 2023
Background Recent reports of individuals experiencing suicidal and/or self-injurious behaviors while using liraglutide and semaglutide have heightened the concerns regarding neuropsychiatric safety of Glucagon-like peptide-1 agonists (GLP-1RAs).
Congqin Chen, Rijing Zhou, Fang Fu, Jie Xiao   +3 more
doaj   +1 more source

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial [PDF]

, 2016
Aims/hypothesis: This study aimed to investigate the acute renal effects of the glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide in type 2 diabetes patients. Methods: We included overweight (BMI 25–40 kg/m2) men and postmenopausal women, aged
A. H. Jan Danser, Daniël H. van Raalte, Jaap A. Joles, Lennart Tonneijck, Marcel H. A. Muskiet, Mark H. H. Kramer, Mark M. Smits, Michaela Diamant, Trynke Hoekstra   +8 more
core   +5 more sources

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential [PDF]

International Journal of Biological Sciences, 2021
Type 2 diabetes mellitus (T2DM) is closely associated with cardiovascular diseases (CVD), including atherosclerosis, hypertension and heart failure. Some anti-diabetic medications are linked with an increased risk of weight gain or hypoglycemia which may reduce the efficacy of the intended anti-hyperglycemic effects of these therapies.
Ma, X, Liu, Z, Ilyas, I, Little, PJ, Kamato, D, Sahebka, A, Chen, Z, Luo, S, Zheng, X, Weng, J, Xu, S   +10 more
openaire   +3 more sources

Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists : a real-world study in 66 583 patients [PDF]

, 2017
Background Real world outcomes of addition or switch to insulin therapy in type 2 diabetes (T2DM) patients on glucagon-like paptide-1 receptor agonist (GLP-1RA) with inadequately controlled hyperglycaemia, are not known.
American Diabetes Association, Balena, Balkau, Crawford, Davis, Drucker, Eng, Fox, Garber, Gautier, Inzucchi, Kamal, Khunti, Lee, Li, Monami, Paul, Paul, Paul, Rigato, Shaefer, Shah, Smilowitz, Thong, Turnbull, Vora   +25 more
core   +1 more source